DETAILED DESCRIPTION What we claim is: 1.
A method for the treatment of stroke, hypoglycemia, ischemic attack or anoxia comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or a compound of formula II, wherein R.
sup.
1, R.
sup.
2, R.
sup.
3 and R.
sup.
4 are independently selected from hydrogen, (1-3C)perfluoroalkyl, halo, nitro and cyano; R.
sup.
5 is selected from hydrogen and (1-6C)alkyl; R.
sup.
6 and R.
sup.
7 are independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl(1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl and CH.
sub.
2 Y wherein Y is selected from (CHOH).
sub.
n CH.
sub.
2 OH and (CH.
sub.
2).
sub.
m R.
sup.
c wherein m is 0 to 5, n is 1 to 5 and R.
sup.
c is selected from hydroxy, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, carboxy, and NR.
sup.
d R.
sup.
e in which R.
sup.
d and R.
sup.
e.
are independently selected from hydrogen and (1-4C)alkyl or R.
sup.
d and R.
sup.
e together with the nitrogen atom to which they are attached, form a saturated 5-, 6- or 7-membered heterocyclic ring which optionally contains one additional heteroatom selected from nitrogen, oxygen and sulfur; or R.
sup.
6 and R.
sup.
7 together with the nitrogen atom to which they are attached, form a 5-, 6- or 7-membered heterocyclic ring which is bonded to said compound through said nitrogen atom, said heterocyclic ring optionally containing one additional heteroatom selected from nitrogen, oxygen and sulfur, and wherein said heterocyclic ring may be substituted with 0-2 substituents selected from (1-6C)alkyl, phenyl, phenyl(1-4C)alkyl, phenoxy and phenyl(1-4C)alkoxy; R.
sup.
8 is selected from hydrogen, halo, (1-6C)alkyl which may optionally bear a substituent selected from amino, formyl, acetyl, propanoyl,isopropanoyl, butyryl, isobutyryl, pentanoyl, pivaloyl, carboxy and carboxamido, aryl(1-6C)alkyl and heteroaryl(1-6C)alkyl; and wherein each aryl moiety is selected from phenyl and naphthyl; each heteroaryl moiety is selected from pyridyl, pyrrolo, pyrazinyl, pyrimidinyl, pyridazinyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl and triazolyl; and wherein each aryl or heteroaryl moiety may be substituted with 0-2 substituents selected from halo, cyano, hydroxy, carboxy, nitro, (1-6C)alkyl, (1-6C)alkoxy, (2-6C)alkenyl, phenyl, phenyl(1-4C)alkyl, phenoxy, phenyl(1-4C)alkoxy and (1-6C)alkoxycarbonyl; or a pharmaceutically acceptable salt thereof; provided that in compounds of formula II, R
|
Vasodialators 
